MX383762B - Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. - Google Patents

Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.

Info

Publication number
MX383762B
MX383762B MX2020005735A MX2020005735A MX383762B MX 383762 B MX383762 B MX 383762B MX 2020005735 A MX2020005735 A MX 2020005735A MX 2020005735 A MX2020005735 A MX 2020005735A MX 383762 B MX383762 B MX 383762B
Authority
MX
Mexico
Prior art keywords
glutarimide derivatives
general formula
methods
producing
derivatives
Prior art date
Application number
MX2020005735A
Other languages
English (en)
Other versions
MX2020005735A (es
Inventor
Tatyana Alexandrovna Kromova
Vladimir Evgenievich Nebolsin
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2013116826A external-priority patent/RU2562773C3/ru
Application filed by Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises filed Critical Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Publication of MX2020005735A publication Critical patent/MX2020005735A/es
Publication of MX383762B publication Critical patent/MX383762B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se relaciona con derivados de glutarimida biológicamente activos novedosos de formula general (I) o sales farmaceuticamente aceptables de los mismos, el uso de los mismos como agentes para tratar enfermedades del tracto respiratorio superior, composiciones farmaceuticas que contienen derivados de glutarimida de formula general (I) y metodos para producir derivados de glutarimida de formula general (I) calentando una monoamida de ácido dicarboxilico de formula general (II) con un agente deshidratante.
MX2020005735A 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. MX383762B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013116826A RU2562773C3 (ru) 2013-04-12 Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
PCT/RU2014/000264 WO2014168522A1 (ru) 2013-04-12 2014-04-10 Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения

Publications (2)

Publication Number Publication Date
MX2020005735A MX2020005735A (es) 2021-06-21
MX383762B true MX383762B (es) 2025-03-14

Family

ID=51689819

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2015014336A MX380619B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
MX2020005738A MX385329B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
MX2020005736A MX383551B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
MX2020005735A MX383762B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2015014336A MX380619B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
MX2020005738A MX385329B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
MX2020005736A MX383551B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida

Country Status (16)

Country Link
US (8) US9815814B2 (es)
EP (3) EP2985282A4 (es)
JP (4) JP6529958B2 (es)
KR (3) KR102254315B1 (es)
CN (4) CN110128406B (es)
AU (5) AU2014251442A1 (es)
BR (3) BR122020010210B1 (es)
CA (1) CA2909057C (es)
EA (4) EA033054B1 (es)
ES (1) ES2988541T3 (es)
IL (4) IL266301B2 (es)
MX (4) MX380619B (es)
SG (4) SG10201802650WA (es)
UA (1) UA121299C2 (es)
WO (1) WO2014168522A1 (es)
ZA (3) ZA201508278B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2985282A4 (en) * 2013-04-12 2017-02-22 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
MD4788C1 (ro) * 2017-09-07 2022-09-30 Ооо "Валента-Интеллект" Utilizarea derivatului de glutarimidă pentru tratarea afecţiunilor, legate de activitatea aberantă a citokinelor
US12378203B2 (en) 2018-11-01 2025-08-05 Ahammune Biosciences Private Limited Imidazole compounds, process for the synthesis and uses thereof
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
WO2021262040A1 (ru) * 2020-06-26 2021-12-30 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
WO2023121519A1 (ru) * 2021-12-23 2023-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-диона для лечения covid-19
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение
WO2023249516A1 (ru) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новая кристаллическая форма 1-[2-(1-метилимидазол-4-ил)этил]пергидроазин-2,6-диона и ее фармацевтическое применение
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081308A (en) * 1959-12-29 1963-03-12 Searle & Co 5-carbocyclic-3-imidomethyloxazolidines and process
US3171839A (en) * 1961-05-18 1965-03-02 Searle & Co 4-alkyl-1-(cyclic imidoalkyl) piperidines
GB1033251A (en) * 1961-09-07 1966-06-22 Distillers Co Yeast Ltd Glutarimide derivatives
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
US4261990A (en) * 1979-03-09 1981-04-14 Ciba-Geigy Corporation N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
JPS606686A (ja) * 1983-06-27 1985-01-14 Kissei Pharmaceut Co Ltd チオフエン誘導体及びその製造方法
JPS6066686A (ja) 1983-09-19 1985-04-16 Toshiba Corp ライン駆動電動機の速度制御装置
SE8600261D0 (sv) * 1986-01-21 1986-01-21 Lundblad Leif Indolokinoxaliner med substituenter i 6-position som innehaller cykliska grupper
SU1836365A3 (ru) * 1991-01-24 1993-08-23 Физиko-Xиmичeckий Иhctиtуt Иm.A.B.Бoгatckoгo;Hии@ Фapmakoлoгии Poccийckoй Amh Способ получения ν-0-пиперазинил)бутилглутаримидов
FR2737725B1 (fr) 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
AU8998598A (en) * 1997-09-11 1999-03-29 Nissan Chemical Industries Ltd. Pyrazole compounds and plant disease control agent
ITMI991578A1 (it) * 1999-07-15 2001-01-15 Recordati Ind Chimica E Farma Amidi e imidi cicliche dotate di attivita' antagonista selettiva per il recettore adrenergico
US6413428B1 (en) 1999-09-16 2002-07-02 Berger Instruments, Inc. Apparatus and method for preparative supercritical fluid chromatography
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
WO2004022536A1 (en) * 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
RU2337908C2 (ru) * 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
CN1260218C (zh) * 2003-11-06 2006-06-21 天津药物研究院 一类pdf酶抑制剂－异羟肟酸系列化合物及其合成方法与用途
WO2006040646A1 (en) * 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
KR100917511B1 (ko) * 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
WO2010033340A1 (en) * 2008-09-16 2010-03-25 The Trustees Of The University Of Pennsylvania Influenza a virus inhibition
EA025224B1 (ru) * 2010-04-15 2016-12-30 Байота Сайентифик Менеджмент Пти Лтд. ПРИМЕНЕНИЕ 3-ЭТОКСИ-6-{2-[1-(6-МЕТИЛПИРИДАЗИН-3-ИЛ)ПИПЕРИДИН-4-ИЛ]ЭТОКСИ}БЕНЗО[d]ИЗОКСАЗОЛА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ПРИ ЛЕЧЕНИИ ИЛИ ОБЛЕГЧЕНИИ СИМПТОМОВ АСТМЫ
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
US20120157382A1 (en) * 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
EP2985282A4 (en) * 2013-04-12 2017-02-22 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Also Published As

Publication number Publication date
BR112015025804B1 (pt) 2022-01-04
WO2014168522A9 (ru) 2014-12-04
EA032938B1 (ru) 2019-08-30
US10377739B2 (en) 2019-08-13
IL266302A (en) 2019-06-30
EA033054B1 (ru) 2019-08-30
KR102296182B1 (ko) 2021-09-02
US9815814B2 (en) 2017-11-14
CA2909057C (en) 2022-03-22
CN110128406A (zh) 2019-08-16
MX2020005736A (es) 2021-06-14
EA032951B1 (ru) 2019-08-30
IL241998B (en) 2019-06-30
CN110128406B (zh) 2021-08-27
EP3725785A1 (en) 2020-10-21
AU2018236805A1 (en) 2018-10-18
JP2019034964A (ja) 2019-03-07
US10155743B2 (en) 2018-12-18
US20160046598A1 (en) 2016-02-18
JP6843103B2 (ja) 2021-03-17
US10155747B2 (en) 2018-12-18
BR122020010210B1 (pt) 2022-09-20
CA2909057A1 (en) 2014-10-16
SG10201802648SA (en) 2018-05-30
EA031392B1 (ru) 2018-12-28
EP2985282A1 (en) 2016-02-17
AU2020203630A1 (en) 2020-06-25
IL266302B (en) 2021-09-30
AU2014251442A1 (en) 2015-12-03
US20180016253A1 (en) 2018-01-18
SG10201802650WA (en) 2018-05-30
EP2985282A4 (en) 2017-02-22
CN106061962B (zh) 2019-09-06
RU2562773C2 (ru) 2015-09-10
US20180022728A1 (en) 2018-01-25
JP6620324B2 (ja) 2019-12-18
WO2014168522A1 (ru) 2014-10-16
IL266301A (en) 2019-06-30
KR20160021092A (ko) 2016-02-24
MX2020005735A (es) 2021-06-21
IL266300A (en) 2019-06-30
AU2020203968B2 (en) 2021-04-22
EP3722290A1 (en) 2020-10-14
EA201792072A2 (ru) 2018-04-30
US10155745B2 (en) 2018-12-18
IL266300B (en) 2021-10-31
US10155746B2 (en) 2018-12-18
MX383551B (es) 2025-03-14
IL266301B2 (en) 2023-03-01
AU2020203632A1 (en) 2020-06-25
SG10201802647QA (en) 2018-05-30
MX380619B (es) 2025-03-12
IL266301B (en) 2022-11-01
ZA201603108B (en) 2017-08-30
ZA201603109B (en) 2017-08-30
KR20200069381A (ko) 2020-06-16
RU2013116826A (ru) 2014-10-20
CN110172055A (zh) 2019-08-27
CN110229140B (zh) 2022-06-10
JP6529958B2 (ja) 2019-06-12
ES2988541T3 (es) 2024-11-20
AU2018236805B2 (en) 2020-04-09
EA201792071A2 (ru) 2018-04-30
AU2020203968A1 (en) 2020-07-02
EA201792597A2 (ru) 2018-04-30
EP3725785C0 (en) 2024-04-10
CN110229140A (zh) 2019-09-13
KR102255929B1 (ko) 2021-05-26
ZA201508278B (en) 2017-11-29
EA201792071A3 (ru) 2018-09-28
SG11201508394UA (en) 2015-11-27
AU2020203632B2 (en) 2021-04-22
US10196377B2 (en) 2019-02-05
EA201792597A3 (ru) 2018-09-28
UA121299C2 (uk) 2020-05-12
JP2016516766A (ja) 2016-06-09
JP2019034966A (ja) 2019-03-07
CN110172055B (zh) 2021-10-29
AU2020203630B2 (en) 2021-04-22
WO2014168522A4 (ru) 2015-01-22
BR122020010204B1 (pt) 2022-03-03
EA201591957A1 (ru) 2016-02-29
JP2019034965A (ja) 2019-03-07
AU2018236805C1 (en) 2020-11-05
CN106061962A (zh) 2016-10-26
JP6627039B2 (ja) 2020-01-08
EA201792072A3 (ru) 2018-09-28
EP3722290B1 (en) 2023-06-21
KR102254315B1 (ko) 2021-05-25
KR20200069380A (ko) 2020-06-16
US20190084961A1 (en) 2019-03-21
EP3725785B1 (en) 2024-04-10
US20180016257A1 (en) 2018-01-18
MX2020005738A (es) 2021-08-13
US20180016255A1 (en) 2018-01-18
US20180016254A1 (en) 2018-01-18
MX385329B (es) 2025-03-18
US20180016256A1 (en) 2018-01-18
BR112015025804A2 (pt) 2017-07-25
MX2015014336A (es) 2016-06-07
US10155744B2 (en) 2018-12-18

Similar Documents

Publication Publication Date Title
MX383762B (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
MX373711B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201491671A1 (ru) Гетероциклильные соединения
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
BR112015004529A8 (pt) alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
EA201591195A1 (ru) Новые хинолоновые производные
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
EA201600434A1 (ru) Применение производных бензимидазолпролина
TR201902057T4 (tr) Tetrasiklin bileşikleri.
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
TH129186A (th) สารประกอบเฮทเทอโรไซคลิก (heterocyclic compounds) ซึ่งมีประโยชน์เป็นสารยับยั้ง pdk1 (pdk1 inhibitors)
TH158493A (th) อนุพันธ์ของ 1,2,4-ไตรอะซีน สำหรับการบำบัดของโรคติดเชื้อไวรัส
TH148359A (th) ไพรโรลิดีน-2-คาร์บอกซาไมด์ที่ถูกแทนที่